Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 11, 2012 8:40pm
156 Views
Post# 20475821

RE: Brigus Arranges $10-million Private Placement

RE: Brigus Arranges $10-million Private Placement

Kwel2:

 

16.8% gives us an indication that the Toronto brokers are aware of the upside potential of BRD.

 

We now know the contents of the Ore Reserve Plan being used for the (non- SSL streaming)  C147 Zone. The benefit to BRD should be significant as it is potentially a high grade open pit  with the potential to reduce BF UG HG production (paying into the stream); all contingent on available (Timmins/ValD'or) mill capacity.

 

Anyone know where the closest toll mill is in the Hislop area? Anyone know where a portable mill can be found? Shafts ( for ore below 400m) and Mills (for production over 2200k) are potential ways of optimized production going foward.

 

BWDIK?? EXPECTED is not a mining term (that I'm familiar with)... vis a vis PLANNED, BUDGETED, FORECAST, etc. Just like ore lost in a stope is not SANITIZED vis a vis STRANDED or CAPTIVE. The march to production cost reduction IS a regular (every minute) consideration. 

 

Constant improvement is the preferred way to achieving a sub $700 target.  In the Exall/Glimmer (1999 to 2002) production this target was in the $200 range.  Purchasing (aka Materials Management) decisions and joint efforts

 

Cheers

Stanley

Bullboard Posts